Dr. Mason Lu is the Founder, President, and CEO of MedAbome, Inc.

A recognized expert in immunology, oncology, antibody science and technology, Dr. Lu brings over 30 years of experiences in the discovery and development of therapeutic antibodies. He is the original inventor of EBGLYSS® (lebrikizumab) and contributed to antibody validation and assay development of Xolair® (omalizumab), Ligelizumab, and Trogarzo® (ibalizumab). He also holds co-inventorships for numerous other antibody drug candidates currently in various stages of clinical development.

Dr. Lu is a serial entrepreneur who previously founded two successful antibody companies in China before establishing MedAbome, Inc. His prior roles include serving as Scientist and Research Manager II at Tanox/Genentech, Inc., and as Assistant Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Lu earned his Ph.D. from the Medical Research Council Laboratory of Molecular Biology (MRC-LMB) and the University of Cambridge, his M.D. from Shanghai Second Medical University, and his M.Sc. from the Shanghai Cancer Institute. He completed postdoctoral training at Baylor College of Medicine.